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Abstract
Background: Drug resistant tuberculosis (TB), particularly multidrug resistant (MDR) represents a major global
public health problem particularly in developing countries like Pakistan. Different studies have found that Drug
resistant TB is associated with a higher risk of treatment failure and death. This study was done to determine the
magnitude of drug resistance among retreatment cases. Objective: To determine the frequency of drug resistance
in re-treatment cases of pulmonary tuberculosis by using the Drug Sensitivity Test (DST). Material and
methods: Tubes containing LJ medium were separately supplemented with following drugs in each tube
(Streptomycin 10 µg, Isoniazid 1 µg, Ethanbutaol 10 µg, Rifampicin 1 µg, Pyrazinamide 100 µg, Ethionamide 5
µg, Kanamycin 6 µg, Amikacin 6 µg, Ofloxacin 1 µg, Capremycin 10 µg). Any amount of growth observed in
any tube with drug was considered as Resistant. If no growth observed in any of those tubes then it was Sensitive.
Results: Of these 265 study cases, 157 (59.2) were male patients and 108 (40.8%) were female patients. Mean
age of our study cases was 34.16 ± 8.24 years (with minimum age was 20 years while maximum age was noted
to be 48 years). Mean weight of our study cases was 59.38 ± 7.54 Kg (with minimum weight was 48 Kg while
maximum weight was 75 Kg). Of these 265 retreatment cases, 74 (27.9%) were of treatment failure, with relapse
53 (20%) and 138 (52.1%) were defaulters of the treatment. Drug resistance was noted in 170 (64.2%) of our
study cases while 95 (35.8%) showed drug sensitivity. Conclusion: Very High frequency of drug resistance was
observed among retreatment patients in our study. Failure to the compliance with treatment (defaulter of
treatment) was major risk factor observed in our study. Drug resistance was significantly associated with
increasing age, relapse of tuberculosis, defaulter of treatment and diabetes mellitus. More studies are required
from different parts of Pakistan to generate database at National level to combat this menace. There is a need to
design well directed massive awareness campaign to educate general public and to bring awareness among
targeted population.
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Introduction:
Global burden of Tuberculosis (TB) cases and drug resistance are increasing.(1) Most of this burden is in the
resource poor and under developed countries where tuberculosis kills more people than any other single infection.
Traditional sputum smear microscopy is the only laboratory test for TB that is accessible to most of the world’s
population. Smear microscopy is inexpensive and highly specific, so positive results almost always prompt
treatment. However, smear microscopy has low sensitivity and cannot test for drug resistance, which is
important because patients with drug resistant TB require prompt second-line treatment to prevent morbidity,
mortality and thereby preventing dissemination of multi-drug-resistant tuberculosis (MDR-TB) and extensively
drug-resistant tuberculosis (XDR-TB).(2,3)
An alarming increase in the global incidence of drug-resistant tuberculosis has created a critical need to
detect tuberculosis and identify drug-resistant cases.(4) . The recent discovery of large numbers of cases of
multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) TB in South Africa likely represents an
unrecognized and evolving epidemic rather than sporadic, localized outbreaks.(5) Failure to quickly and
effectively recognize and treat patients with drug-resistant tuberculosis leads to increased mortality, nosocomial
outbreaks, and resistance to additional anti-tuberculosis drugs.(6,7) . However, MDR and XDR tuberculosis can be
treated and its spread can be prevented if properly identified at an early stage. This test uses the DST, which
provides results after six weeks. Rifampicin resistance is an excellent marker for for multi drug resistant
Mycobactarium tuberculosis, as 90% of rifampicin resistant Mycobactarium tuberculosi sstrains are also
isoniazid resistant, and hence, are classified as multi drug resistant(8) Isoniazid (INH) and Rifampicin (RIF) are
the backbone of the standard regimen for treating tuberculosis (TB), and resistance to these drugs indicates a
necessity for alteration of the standard regimen. (9). Ideally, a treatment regimen for drug resistant TB would be
designed and initiated based on in vitro drug susceptibility test results for each patient’s M .tuberculosis isolate
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(10)The choice of drugs would be based on the pattern of drug resistance which drugs have been taken previously
Whether the patient has underlying medical conditions The adverse effects associated with the drug In order to
treat patients properly and to reduce further spread of drug-resistant TB, it is clinically important to provide
susceptibility results to health care providers. In a prevous study the frequency of drugs resistance in re-treatment
cases is 52% (11) in Dehli, India. In another study at Haryana, India the frequency of drugs resistance in re-
treatment cases is 75%.(12) In a previous study the frequency of drugs resistance in re-treatment cases is 45.6%
in Istanbul ,Turkey.(13) In another study conducted in Makassar Indonesia the frequency of drug resistance in re-
treatment cases is 59.6%(14).
Materials and methods:
The patients were enrolled from the outpatient department of Mayo Hospital, Lahore. Patient with co-morbid
diseases like Chronic liver disease, chronic renal failure and congestive cardiac failure and pregnant women
were excluded from our study. The demographic data like age, sex and weight of the patients was collected.
Patients fulfilling inclusion and exclusion criteria were included in study. Tubes containing LJ medium were
separately supplemented with following drugs in each tube (Streptomycin 10 µg, Isoniazid 1 µg, Ethanbutaol 10
µg, Rifampicin 1 µg, Pyrazinamide 100 µg, Ethionamide 5 µg, Kanamycin 6 µg, Amikacin 6 µg, Ofloxacin 1 µg,
Capremycin 10 µg). Any amount of growth observed in any tube with drug was considered as Resistant. If no
growth observed in any of those tubes then it was Sensitive. Re-treatment Cases: included relapse / treatment
failure and defaulter cases. Treatment failure was defined as a patient whose sputum smear was positive at fifth
month or later during treatment. A patient previously treated for TB who has been declared cured or treatment
completed, and was diagnosed with bacteriologically positive (smear or culture) tuberculosis was defined as
relapse. Defaulter was defined as a patient who returned to treatment, bacteriologically positive by sputum smear
microscopy or culture, following interruption of treatment for two or more consecutive months. Sputum
samples were collected as per WHO instructions. The sputum sample were sent to Provincial Reference
laboratory of the Hospoital for culture and DST. The report was assessed for detection of MTB and drugs
resistance. All the data was entered in a specifically designed proforma. Descriptive statistics was applied. Data
was entered using software SPSS version 10. Numerical data like age and weight were described in terms of
mean and standard deviation. The nominal data like gender and drugs resistance detection on drug sensitivity
were described as frequencies and percentages.
Results:
Our study included a total of 265 patients re-treatment cases of pulmonary TB meeting inclusion and exclusion
criteria of our study. Of these 265 study cases, 157 (59.2%) were male patients and 108 (40.8%) were female
patients. Mean age of our study cases was 34.16 ± 8.24 years ranging from 20 years to 48 years. Mean age of the
male patients was 32.43 ± 7.75 years while that of female patients was 36.69 ± 8.33 years (p=0.000) while 140
(52.8%) were less than 35 years of the age. Mean weight of our study cases was 59.38 ± 7.54 Kg ranging from
48 Kg to 75 Kg while 171 (64.5%) had weight ranging from 40 to 60 kilograms. Of these 265 retreatment cases,
74 (27.9%) were of treatment failure, with relapse 53 (20%) and 138 (52.1%) were defaulters of the treatment.
Of these 265 study cases, 52 (19.6%) were diabetic patients and 48 (18.1%) had history of hypertension. Drug
resistance was noted in 170 (64.2%) of our study cases while 95 (35.8%) showed drug sensitivity.
Table No. 1
Stratification of gender with regards to drug resistance
Gender
Drug Resistance
P- valueResistant
(n=170)
Sensitive
(n=95)
Male
(n=157)
95 62
0.153Female
(n=108)
75 33
Total 265
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Table No. 2
Stratification of age with regards to drug resistance
Age groups
Drug Resistance
P- valueResistant
(n=170)
Sensitive
(n=95)
18-36 Years
(n=140)
75 65
0.00036-50 Years
(n=125)
95 30
Total 265
Table No. 3
Stratification of treatment failure with regards to drug resistance
(n=265)
Treatment
failure
Drug Resistance
P – valueResistant
(n=170)
Sensitive
(n=95)
Yes
(n=74)
52 22
0.253
No
(n=191)
118 73
Total 265
Table No. 4
Stratification of relapse with regards to drug resistance
(n=265)
Relapse of TB
Drug Resistance
P – valueResistant
(n=170)
Sensitive
(n=95)
Yes
(n=53)
42 11
0.011
No
(n=212)
128 84
Total 265
Table No. 5
Stratification of defaulter of treatment with regards to drug resistance
(n=265)
Defaulters
Drug Resistance
P – valueResistant
(n=170)
Sensitive
(n=95)
Yes
(n=138)
76 62
0.001
No
(n=127)
94 33
Total 265
Discussion:
Male gender predominance has been reported to occur more frequently in retreatment cases of pulmonary TB in
different parts of the world. Our study included 157 (59.2) male patients and 108 (40.8%) were female patients.
A study conducted by Anyama et al 15 also reported higher proportion of male patients (75%), similar to that of
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our study results. Abdella et al 16 reported 60.8 % male patients with retreatment of pulmonary TB, these
findings are similar to that of our study results. Similar results have been reported in other studies as well 17, 18.
Our study results are in compliance with that of reported by
Mean age of our study cases was 34.16 ± 8.24 years (with minimum age was 20 years while maximum age
was noted to be 48 years). Mean age of the male patients was 32.43 ± 7.75 years while that of female patients
was 36.69 ± 8.33 years (p=0.000). Abdella et al 16 reported 31.67 ± 10.02 years, close to our results. Similar
results have been reported by Anyama et al 15. Mean weight of our study cases was 59.38 ± 7.54 Kg (with
minimum weight was 48 Kg while maximum weight was 75 Kg). Our study results have indicated that majority
of our study cases i.e. 171 (64.5%) had weight ranging from 40 to 60 kilograms.
Of these 265 retreatment cases, 74 (27.9%) were of treatment failure. Abdella et al from Ethiopia reported
43 % treatment failure among retreatment cases. These values are quite higher than that of our study results. 16 In
our study patients with relapse were 53 (20%) while a study conducted by Abdella et al 16 reported fairly high
proportion of relapse to be 46 %. In our study, 138 (52.1%) were defaulters of the treatment. Singhai et al from
India 18 reported 46 % frequency of defaulters which predominated relapse, these findings are in compliance to
our study results. Meskel et al 19 also reported defaulters predominantly in high proportion which is consistent
with our findings while Abdella et al reported only 10 % defaulter rate in their study. A study conducted by
Chiang et al 20 reported same findings as ours.
Of these 265 study cases, 52 (19.6%) were diabetic patients. Anyama et al 16 reported 20 % frequency of
diabetes in retreatment cases in 2 hospitals, these findings are close to that of our study results. In our study, 48
(18.1%) had history of hypertension.
In literature different studies have reported high proportions of drug resistance among retreatment cases.
Drug resistance was noted in 170 (64.2%) of our study cases while 95 (35.8%) showed drug sensitivity. Abdella
et al 16 reported 58.6 % rate of drug resistance in their study, our study results are in compliance with that of
Abdella et al. a study conducted by Chiang et al 20 reported 43 % drug resistance among retreatment cases. An
Indian study conducted by Janmeja et al12 reported 75 % drug resistance among treatment failure patients which
is close to our findings while Singhai et al 18 from India reported 47 % drug resistance among retreatment cases.
Sevam et al 13 from Turkey reported 45.6 % frequency of drug resistance among retreatment cases. Meskel et al
19 reported 53.6% drug resistance among retreatment patients.
Conclusion:
Very High frequency of drug resistance was observed among retreatment patients in our study. Failure to the
compliance with treatment (defaulter of treatment) was major risk factor observed in our study. Drug resistance
was significantly associated with increasing age, relapse of tuberculosis, defaulter of treatment and diabetes
mellitus. More studies are required from different parts of Pakistan to generate database at National level to
combat this menace. There is a need to design well directed massive awareness campaign to educate general
public and to bring awareness among targeted population.
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